The Online Investor

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Fri., Jan. 21, 12:29 AM

Slide #23. Relmada Therapeutics, Inc. Secondary Offering

Company: Relmada Therapeutics, Inc. (NASDAQ:RLMD)
Date announced: 12/8/2021
Shares Offered: 8,823,530
Date of Pricing: 12/8/2021
Price Per Share: $17.00
Secondary Offering Details: Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced its intention to offer and sell $100 million of shares of its common stock in an underwritten public offering pursuant to its existing shelf registration statement. Relmada also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering on the same terms and conditions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the size or terms of the offering. -updated 12/8- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced the pricing of an upsized underwritten public offering of 8,823,530 shares of its common stock at a public offering price of $17.00 per share. The gross proceeds to Relmada from the offering, before deducting underwriting discounts and commissions and other expenses payable by Relmada, are expected to be approximately $150 million. All of the shares in the offering are being sold by Relmada. The offering is expected to close on December 13, 2021, subject to customary closing conditions. In addition, Relmada has granted the underwriters a 30-day option to purchase up to an additional 1,323,529 shares of Relmada's common stock at the public offering price, less underwriting

Relmada Therapeutics is a biotechnology company focused on the development of d-methadone (dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Co.'s product candidate, d-methadone, is a new chemical entity being developed as an oral agent for the treatment of depression and other potential indications. Co.'s product portfolio also includes: d-methadone (dextromethadone, REL-1017), a NMDA receptor antagonist for treating depression and neuropathic pain; LevoCap ER (REL-1015), an abuse resistant, sustained release dosage form of the opioid analgesic levorphanol; and BuTab (oral buprenorphine, REL-1028), an oral dosage form of the opioid analgesic buprenorphine.

RLMD SEC Filing Email Alerts Service

Open the RLMD Page at The Online Investor »

Company Name: 
Relmada Therapeutics Inc
Website: 
www.relmada.com
Sector: 
Biotechnology
Number of ETFs Holding RLMD: 
22
Total Market Value Held by ETFs: 
$33.31M
Total Market Capitalization: 
$331.00M
% of Market Cap. Held by ETFs: 
10.06%
 

Open the RLMD Page at The Online Investor (in a new window) »

Quotes delayed 20 minutes

Email EnvelopeFree RLMD Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Strong Buy (4.00 out of 4)
76th percentile
(ranked higher than approx. 76% of all stocks covered)

Analysts' Target Price:
RLMD Stock Forecast

Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2022, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.